Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming when stakes are high
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
October 30, 2025
Cardiovascular Today—October 30, 2025
October 30, 2025
Lucid Diligence Brief: Novo Nordisk proposal to acquire Metsera
October 30, 2025
Cell and Gene Therapy Video Recap—October 30, 2025
October 30, 2025
Cell and Gene Therapy Today—October 30, 2025
October 30, 2025
Women’s Health Video Recap—October 29, 2025
October 30, 2025
Lucid Diligence Brief: ModeX Therapeutics and Regeneron collaboration
October 29, 2025
Lucid Diligence Brief: Lilly and NVIDIA AI Supercomputer partnership
October 29, 2025
Neuroscience Video Recap—October 29, 2025
October 29, 2025
Immunology Today — October 29, 2025
October 29, 2025
Neuroscience Today — October 29, 2025
October 29, 2025
Lucid Diligence Brief: GSK licenses Empirico’s siRNA in COPD
October 28, 2025